• Explore /
  • Poster
  • / Analyzing the relationship of response and survival in patients with refractory or relapsed and refractory multiple myeloma (RRMM) treated with pomalidomide plus low-dose dexamethasone (POM + LoDEX) in the MM-003 trial.

Analyzing the relationship of response and survival in patients with refractory or relapsed and refractory multiple myeloma (RRMM) treated with pomalidomide plus low-dose dexamethasone (POM + LoDEX) in the MM-003 trial.

Abstract Poster

Authors

null

Katja Weisel

University Hospital of Tuebingen, Tuebingen, Germany

Katja Weisel , Philippe Moreau , Craig J Gibson , Kevin W. Song , Owain Saunders , Lars Axel Sternas , Kevin Hong , Mohamed H. Zaki , Meletios A. Dimopoulos

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT01311687

Citation

J Clin Oncol 33, 2015 (suppl; abstr 8593)

DOI

10.1200/jco.2015.33.15_suppl.8593

Abstract #

8593

Poster Bd #

411

Abstract Disclosures

Similar Posters

First Author: Gareth J Morgan

First Author: Kevin W. Song

First Author: Dan T. Vogl

First Author: David Siegel